Promoting research partnerships 

to improve veterans’ health

NAVREF News Center

<< First  < Prev   1   2   Next >  Last >> 
  • 20 Oct 2017 10:51 AM | Hawk Tran (Administrator)

    The FY17 Defense Appropriations Act provides $5 million (M) to the Department of Defense Lupus Research Program (LRP) to support innovative and impactful research that addresses fundamental issues in lupus.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    FY17 LRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website. 

    Applications submitted to the FY17 LRP must address at least one of the three Focus Areas listed below:

    •           Understand lupus disease heterogeneity including, but not limited to, progressive stages of lupus disease over time, strategies and technologies to subtype patients, lupus disease mechanisms, biopsychosocial studies, personalized medicine, variation in treatment and its effects on patient outcomes, socioeconomic studies, environmental studies, and epidemiological studies.

    •           Understand how the underlying genetic components of lupus disease relate to clinical disease characteristics using functional genomic studies.

    •           Determine the pathobiology of lupus in target human tissues including, but not limited to, imaging studies, genetics of lupus disease in particular tissues, and metabolomics.

    http://cdmrp.army.mil/funding/lrp

    Concept Award – Letter of Intent Due December 21, 2017, Full Application Due January 4, 2018

    • Investigators at all academic levels
    • Supports high-risk studies that have the potential to reveal new avenues for investigation into lupus.
    • Must describe how the new idea will enhance existing knowledge of lupus.
    • Must address at least one of the FY17 LRP Focus Areas
    • Submission of letter of intent is required prior to full application submission
    • Inclusion of preliminary data is encouraged
    • Clinical trials are not allowed
    • Maximum funding of $150,000 for total costs
    • Maximum period of performance is year

    Impact Award – Letter of Intent Due December 21, 2017, Full Application Due January 4, 2018

    • Assistant Professor level or above (or equivalent)
    • Supports new high-risk, high-reward ideas that could lead to critical discoveries or major advancements in the field of lupus research.
    • Must describe how the new idea will enhance existing knowledge of lupus or develop a novel course of investigation.
    • Emphasis is on impact
    • Must address at least one of the FY17 LRP Focus Areas
    • Submission of letter of intent is required prior to full application submission
    • Inclusion of preliminary data is encouraged
    • Clinical trials are not allowed
    • Maximum funding of $525,000 for total costs
    • Maximum period of performance is 3 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the LRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk

    301-682-5507
    help@eBrap.org


  • 16 Oct 2017 1:43 PM | Hawk Tran (Administrator)

    Washington, D.C. - VA Secretary David Shulkin recognized the National Association of Veterans' Research and Education Foundations (NAVREF) on September 7, 2017 in a letter addressed to VA colleagues and NAVREF conference attendees. Secretary Shulkin acknowledged in the letter that NAVREF's annual conference had played a "significant role in educating research leaders" and that our community should continue "forging new partnerships" as the VA modernizes itself. NAVREF would like to thank Secretary Shulkin for his kinds words and we thank all of our NAVREF members for their dedication and support over the past 25 years. 

    Read the original letter from Secretary Shulkin here. 

  • 18 Sep 2017 11:04 AM | Hawk Tran (Administrator)

    The FY17 Defense Appropriations Act provides $125 million (M) to the Department of Defense Psychological Health and Traumatic Brain Injury Research Program (PHTBIRP). As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation aligned with specific DHA J9 Directorate research program areas, including Joint Program Committee-5/Military Operational Medicine Research Program (JPC-5/MOMRP). This Program Announcement/Funding Opportunity and subsequent awards will be managed and executed by the Congressionally Directed Medical Research Programs (CDMRP) with strategic oversight from JPC-5/MOMRP.  The PH/TBIRP and the JPC-5/MOMRP in collaboration with the Defense Suicide Prevention Office and Service Resiliency Proponents will be seeking applications/proposals to examine the efficacy and effectiveness of peer-to-peer support tools to translate and integrate content into the everyday routines of Service members (SM) to enhance psychological health readiness and mitigate negative behavioral health issues including suicide behaviors.  The expectation of this research is to demonstrate the utility of these peer-to-peer support psychological health readiness tools to benefit our SMs and the public at large.

    The PH/TBIRP and JPC-5/MOMRP are providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY17 PHTBIRP Program Announcement and General Application Instruction for the following award mechanisms are anticipated to be posted on the Grants.gov website in October 2017.  Pre-application and application deadlines will be available when the Program-Specific Broad Agency Announcement is released.  This pre-announcement should not be construed as an obligation by the government.

    Peer Support Program (PSP)Translational Research Award

    • Intramural (DoD) and extramural investigators at all academic levels (or equivalent) are eligible to submit applications
    • Proposals/applications to the FY17 PHTBIRP PSP Translational Research award should examine the efficacy and effectiveness of peer-to-peer support tools to translate and integrate content into the everyday routines of SMs to enhance psychological health readiness and mitigate negative behavioral health issues including suicide behaviors. The expectation of this research is to demonstrate the utility of these peer-to-peer support psychological health readiness tools to benefit our SMs and the public at large.
    • The CDMRP expects to allocate FY17 funding to fund approximately 2-3 PSP translational research awards.  The maximum period of performance is 3 years.  The maximum allowable total costs per award (direct and indirect) for the entire period of performance is $3M

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.For more information about the PHTBIRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 18 Sep 2017 11:03 AM | Hawk Tran (Administrator)

    The FY17 Defense Appropriations Act provides $5 million (M) to the Department of Defense Lupus Research Program (LRP) to support innovative and impactful research that addresses fundamental issues in lupus.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    The LRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY17 LRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in October 2017.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

    Applications submitted to the FY17 LRP must address at least one of the three Focus Areas listed below:

    •           Understand lupus disease heterogeneity including, but not limited to, progressive stages of lupus disease over time, strategies and technologies to subtype patients, lupus disease mechanisms, biopsychosocial studies, personalized medicine, variation in treatment and its effects on patient outcomes, socioeconomic studies, environmental studies, and epidemiological studies.

    •           Understand how the underlying genetic components of lupus disease relate to clinical disease characteristics using functional genomic studies.

    •           Determine the pathobiology of lupus in target human tissues including, but not limited to, imaging studies, genetics of lupus disease in particular tissues, and metabolomics.

     

    Concept Award

    • Investigators at all academic levels

    ·         Supports highly innovative, untested, potentially groundbreaking concepts in lupus research

    ·         Emphasis is on innovation

    ·         Clinical trials are not allowed

    • Preliminary data is discouraged

    ·         Maximum funding of $150,000 for total costs

    • Maximum period of performance is year

     

    Idea Award

    • Investigators at or above Assistant Professor (or equivalent)

    ·         Supports innovative, high-risk/high-reward research

    ·         Emphasis is on impact

    ·         Clinical trials are not allowed

    • Preliminary data is encouraged but not required

    ·         Maximum funding of $525,000 for total costs

    • Maximum period of performance is 3 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the LRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 8 Sep 2017 1:09 PM | Hawk Tran (Administrator)

    The FY17 Defense Appropriations Act provides $10 million (M) to the Department of Defense Orthotics and Prosthetics Outcomes Research Program (OPORP) to support research that evaluates the comparative effectiveness of orthotic and prosthetic clinical interventions using patient-centric outcomes for Service members and Veterans who have undergone limb amputation.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    Focus Areas:  The OPORP will only consider applications that specifically address the critical needs of the Orthotics and Prosthetics Outcomes research community in one or more of the FY17 Focus Areas.  The OPORP will solicit research applications that address at least one of the following FY17 Focus Areas:

    ·         Orthotic or Prosthetic Device Form:  Analysis of variables related to currently available clinical options such as, but not limited to, device size, shape, material, and configuration.

    ·         Orthotic or Prosthetic Device Fit:  Analysis of currently available clinical options that facilitate device fit-related characteristics such as comfort and usability through variables such as human-device interface and component connection.

    ·         Orthotic or Prosthetic Device Function:  Analysis of the variables related to currently available clinical options such as device control, passive response, active/actuated response, power, sensors, overall performance with respect to activities of daily living and other real-world activities.

    Orthotics and Prosthetics Outcomes Research Award – Preproposal 10/20/17

    Funding Level 1/New Investigators:  Investigators that meet the following criteria at the application submission deadline date:

    ·        Are within 5 years of their last training position

    ·        Are able to demonstrate the freedom to pursue research goals outside of a formal mentorship program or arrangement

    ·        Can provide evidence of organizational support, such as start-up funds provided by the institution and/or use of a technician, space, facilities, and resources

    ·        PIs working within a laboratory team are eligible to apply for this award, provided they meet the criteria above.

    ·        Graduate students and postdoctoral fellows are not eligible for this award.

     

    Funding Level 2:  Independent investigators at all academic levels (or equivalent) are eligible to submit applications.

    Funding Level 1/New Investigator Option may support pilot research or research that is already supported by preliminary data and has the potential to make significant advancements toward clinical translation.

    Funding Level 2 Option is supported by preliminary data and has the potential to make significant advancement towards clinical translation.

    The OPORA is focused on outcomes-based best practices through analysis of the merits of prosthetic and orthotic device options currently available, not on the development of new, or the improvement of existing, technology.  The intent of the award is to generate clinically useful evidence that will enhance and optimize patient outcomes.

    Animal studies are not allowed.

     

    Funding Level 1/ New Investigators:

    ·       Maximum funding of $500,000 for total costs.

    ·       Maximum period of performance is 3 years.

    Funding Level 2:

    ·       Maximum funding of $2.5M for total costs.

    ·       Maximum period of performance is 4 years

    •  
    • ·       All direct and indirect costs of any subaward (subgrant or subcontract) must be included in the total direct costs of the primary award.

    The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum number of years allowed per funding level.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that are available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Applications must be submitted through the federal government’s single-entry portal, Grants.gov.   For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the OPORP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk

    301-682-5507
    help@eBrap.org


  • 8 Sep 2017 1:08 PM | Hawk Tran (Administrator)

    The FY17 Defense Appropriations Act provides $10 million (M) to the Department of Defense Kidney Cancer Research Program (KCRP) to support United States Army Medical Research Acquisition Activity (USAMRAA).  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    The KCRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY17 KCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in October 2017.  Pre-application (Letter of Intent) and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

    Consortium Development Award

    • ·         Investigators at or above Assistant Professor (or equivalent)
    • Supports infrastructure development to establish the necessary collaborations among a Coordinating Center and Clinical Sites
    • Multi-institution collaboration required
    • Supports clinical trials of novel interventions with the potential to have a significant impact on patient care in kidney cancer
    • Proposed trials may be Phase 0, Phase 1, or Phase 2

    ·         Minimum of three separate institutes: one Coordinating Center and at least two Clinical Sites (other than the Coordinating Center)

    ·         Maximum funding of $1.6 million total costs

    • ·         Maximum period of performance is 2 years
    • ·         Awardee will be eligible to apply for FY19 Consortium Award, if funds are available

     

    Idea Development Award

    Established Investigators: 

    • ·         Independent investigators at or above the level of Assistant Professor (or equivalent) and 10 years or more from a terminal degree; or
    • ·         Early Career Investigators:
    • ·         Investigators at the level of Assistant Professor, Instructor, or Assistant Research Professor (or equivalent) and less than 10 years from a terminal degree (excluding time spent in medical residency or family medical leave) at the time of application submission deadline are eligible.

    ·         Supports new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer.

    ·         Preliminary data is required; need not be in kidney cancer.

    ·         Innovation and Impact are the most important review criteria.

    ·         Clinical Trials are not allowed

    ·         Areas of Interest include:

    • ·         Microenvironment, Metabolism, Chromatin and Gene Regulation, Rare Cancers, Screening, Early Detection, Novel Imaging Technologies, Liquid Biopsy, Biomarker Development, Prognosis, Targeted Therapies, Immunotherapies, Resistance, Novel Interventions, Surgical, Ablation, Radiation, Prognosis, Managing Toxicity, Survivorship and Patient Experience, Surveillance, Genetic Risk Factors

    ·         Maximum funding of $400,000 in direct costs (plus indirect costs)

    • ·         Period of performance not to exceed 3 years

     

    Concept Award

    • ·         Investigators at all academic levels

    ·         Supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer

    ·         Emphasis on innovation

    ·         Clinical trials not allowed

    ·         Preliminary data not allowed

    • ·         Blinded review

    ·         Maximum funding of $75,000 for direct costs (plus indirect costs)

    • ·         Maximum period of performance is 1 year

     

    Translational Research Partnership

    • ·         Investigators at or above the level of Assistant Professor (or equivalent)
    • Supports partnerships between clinicians and laboratory scientists that accelerate ideas in kidney cancer into clinical applications

    ·         Supports translational correlative studies

    • Preliminary data required
    • ·         Funding for clinical trials not allowed

    ·         Maximum funding of $600,000 for direct costs (plus indirect costs)

    • ·         Maximum period of performance is 3 years

    A pre-application (letter of intent) is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application (letter of intent) deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Applications must be submitted through the Federal Government’s single-entry portal, Grants.gov.  Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the KCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 31 Aug 2017 12:59 PM | Hawk Tran (Administrator)

    The FY17 Defense Appropriations Act provides $10 million (M) to the Department of Defense Hearing Restoration Research Program (HRRP) to support promising, necessary research for the treatment of burdensome and very prevalent auditory system injury that will foster new directions in the field of hearing restoration and propel the science forward to therapeutic interventions that restore auditory function.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    The HRRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY17 HRRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in September 2017.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

    Focus Areas: The HRRP will only consider applications that specifically address the critical needs of the Hearing restoration research community in one or more of the FY17 Focus Areas. The HRRP will solicit research applications that address at least one of the following FY17 Focus Areas:

    • Develop reliable in vitro human models for evaluating hearing restoration therapies

    • Accelerate translation of biological regeneration into therapies that restore auditory function including, for example, treatments that enhance:

    1. Synaptic plasticity

    2. Hair cell and neural regeneration

    • Develop and validate assessment techniques and/or treatment methods that address functional hearing restoration including, for example:

    1. Personalized prognostic indicators of therapeutic success

    2. Better differential diagnostic tests

    3. Improved evaluation of treatment methods

     

    Translational Research Award (TRA)

    • Independent investigators at all academic levels (or equivalent) are eligible to submit applications.

    ·         Pre-application (Letter of Intent) is required.

    ·         Supports preclinical translational research that will accelerate the movement of promising initiatives relevant to hearing restoration into clinical applications.

    ·         In this first year of the program, applications submitted must focus on the development of reliable in vitro human models to evaluate hearing restoration therapies or research that translates biological regeneration initiatives into therapies that restore auditory function.

    • Preliminary data required.

    ·         Maximum funding of $1,000,000 for direct costs (plus indirect costs).

    ·         Maximum period of performance is 3 years.

    • Indirect costs may be proposed in accordance with the institution’s rate agreement.

     

     

    Focused Research Award (FRA)

    • Independent investigators at all academic levels (or equivalent) are eligible to submit applications.

    ·         Pre-application (Letter of Intent) is required.

    ·         Supports functional hearing restoration research that develops and validates assessment techniques and treatment methods using patient-centric outcomes to identify potential predictive indicators for successful treatment of functional auditory system deficits.

    ·         Research in this area should result in refined diagnostic tools and improved evaluation of the effectiveness of therapeutic approaches for functional hearing restoration.

    • Preliminary data required

    ·         Maximum funding of $750,000 for direct costs (plus indirect costs).

    ·         Maximum period of performance is 3 years.

    • Indirect costs may be proposed in accordance with the institution’s rate agreement.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

     


  • 24 Aug 2017 8:56 AM | Hawk Tran (Administrator)

    The FY17 Defense Appropriations Act provides $10 million (M) to the Department of Defense Orthotics and Prosthetics Outcomes Research Program (OPORP) to support research that evaluates the comparative effectiveness of orthotic and prosthetic clinical interventions using patient-centric outcomes for Service members and Veterans who have undergone limb amputation.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    The OPORP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY17 OPORP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in September 2017.  Pre-application and application deadlines will be available when the Program Announcement is released.  This pre-announcement should not be construed as an obligation by the government.

    Focus Areas:  The OPORP will only consider applications that specifically address the critical needs of the Orthotics and Prosthetics Outcomes research community in one or more of the FY17 Focus Areas.  The OPORP will solicit research applications that address at least one of the following FY17 Focus Areas:

    ·         Orthotic or Prosthetic Device Form:  Analysis of variables related to currently available clinical options such as, but not limited to, device size, shape, material, and configuration.

    ·         Orthotic or Prosthetic Device Fit:  Analysis of currently available clinical options that facilitate device fit-related characteristics such as comfort and usability through variables such as human-device interface and component connection.

    ·         Orthotic or Prosthetic Device Function:  Analysis of the variables related to currently available clinical options such as device control, passive response, active/actuated response, power, sensors, overall performance with respect to activities of daily living and other real-world activities.

    Orthotics and Prosthetics Outcomes Research Award

    Funding Level 1/New Investigators:  Investigators that meet the following criteria at the application submission deadline date:

    ·        Are within 5 years of their last training position

    ·        Are able to demonstrate the freedom to pursue research goals outside of a formal mentorship program or arrangement

    ·        Can provide evidence of organizational support, such as start-up funds provided by the institution and/or use of a technician, space, facilities, and resources

    ·        PIs working within a laboratory team are eligible to apply for this award, provided they meet the criteria above.

    ·        Graduate students and postdoctoral fellows are not eligible for this award.

     

    Funding Level 2:  Independent investigators at all academic levels (or equivalent) are eligible to submit applications.

    Funding Level 1/New Investigator Option may support pilot research or research that is already supported by preliminary data and has the potential to make significant advancements toward clinical translation.

    Funding Level 2 Option is supported by preliminary data and has the potential to make significant advancement towards clinical translation.

    The OPORA is focused on outcomes-based best practices through analysis of the merits of prosthetic and orthotic device options currently available, not on the development of new, or the improvement of existing, technology.  The intent of the award is to generate clinically useful evidence that will enhance and optimize patient outcomes.

    Animal studies are not allowed.

     

    Funding Level 1/ New Investigators:

    ·       Maximum funding of $500,000 for total costs.

    ·       Maximum period of performance is 3 years.

    Funding Level 2:

    ·       Maximum funding of $2.5M for total costs.

    ·       Maximum period of performance is 4 years

    •  
    • ·       All direct and indirect costs of any subaward (subgrant or subcontract) must be included in the total direct costs of the primary award.

    The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum number of years allowed per funding level.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the OPORP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 14 Aug 2017 3:31 PM | Hawk Tran (Administrator)

    The FY17 Defense Appropriations Act provides $12 million (M) to the Department of Defense Reconstructive Transplant Research Program (RTRP) to support research of exceptional scientific merit that has the potential to make a significant impact on improving the function, wellness, and overall quality of life for injured military Service members and Veterans, their caregivers and family members, and the American public.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    FY17 RTRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website. 

    Focus Areas:  The FY17 RTRP encourages research projects that specifically address needs in the field of vascularized composite allotransplantation (VCA) in the following focus areas:

    1. Immune system regulation as specifically applied to VCA
    2. Psychosocial considerations and challenges associated with VCA
    3. Develop ex vivo VCA tissue preservation techniques or technologies to extend the time between procurement and transplantation (goal: 24 hours)
    4. Develop pre-habilitation or rehabilitation strategies that improve reconstructive transplant functional outcomes
    5. Develop standardized quantitative functional outcome measures for VCA, especially for face transplant
    6. Graft clinical monitoring – acute and chronic, as applied to VCA

    Concept Award – Letter of Intent due November 15

    • Investigators at or above the level of postdoctoral fellow (or equivalent)
    • Pre-application (Letter of Intent) is required.
    • Supports the exploration of a highly innovative new concept or untested theory that addresses an important problem relevant to reconstructive transplant. 
    • Preliminary data are NOT allowed.
    • Reviewers at both tiers of review will be blinded to the identity of the Principal Investigator (PI), collaborators, and their organizations.
    • Applications must address at least one of the FY17 RTRP Focus Areas.
    • Maximum funding of $200,000 for total costs (direct plus indirect costs)
    • Maximum period of performance is 18 months

    Investigator-Initiated Research Award – Preproposal due September 20

    • Independent investigators at all academic levels (or equivalent)
    • Preproposal is required; full application submission is by invitation only.
    • Supports studies with potential to make an important contribution to the reconstructive transplant research field, patient care, and/or quality of life.
    • Preliminary or published data required.
    • Multiple PI Option supports synergistic partnerships among two to four  investigators collaborating on a single application; multi-institutional collaborations are encouraged
    • Applications must address at least one of the FY17 RTRP Focus Areas.
    • Individual PIs:
    • Maximum funding of $1 million (M) for total costs
    • Maximum period of performance is 3 years
    • Multiple PI Option:
    • Maximum funding of $1.5M for total costs
    • Maximum period of performance is 3 years

    Technology Development Award – Preproposal due September 20

    • Independent investigators at all academic levels (or equivalent)
    • Preproposal is required; full application submission is by invitation only.
    • Supports research critical for the translation of promising preclinical findings into products focused on reconstructive transplantation.
    • Proof of concept must be established.
    • Transition plan is required.
    • Applications must address at least one of the following FY17 RTRP Focus Areas:
    • Develop ex vivo VCA tissue preservation techniques or technologies to extend the time between procurement and transplantation (goal: 24 hours)
    • Graft clinical monitoring – acute and chronic, as applied to VCA
    • Maximum funding of $1M for total costs
    • Maximum period of performance is 3 years

    Qualitative Research Award – Preproposal due September 20

    • Independent investigators at all academic levels (or equivalent)
    • Preproposal is required; full application submission is by invitation only.
    • Supports qualitative research studies that will help researchers and clinicians to better understand the experiences of individuals who are considering or have already received reconstructive transplant surgery.
    • Demonstrated qualitative research experience within the research team is required.
    • Theoretical perspective of qualitative research must be identified.
    • Rigorous and appropriate data collection and data analyses methods are important components.
    • Multiple PI Option supports synergistic partnerships among two to four investigators collaborating on a single application; multi-institutional collaborations are encouraged.
    • Applications must address the following FY17 RTRP Focus Area:
    • Psychosocial considerations and challenges associated with VCA
    • Individual PIs:
    • Maximum funding of $1M for total costs
    • Maximum period of performance is 3 years
    • Multiple PI Option:
    • Maximum funding of $1.5M for total costs
    • Maximum period of performance is 3 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Applications must be submitted through the federal government’s single-entry portal, Grants.govFor email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the RTRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk

    301-682-5507
    help@eBrap.org


  • 9 Aug 2017 9:39 AM | Hawk Tran (Administrator)

    FY17 BCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov. 

    As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA), J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    Applications submitted to the FY17 BCRP must address one or more of the following overarching challenges:

    • Prevent breast cancer (primary prevention)
    • Identify determinants of breast cancer initiation, risk, or susceptibility
    • Distinguish deadly from non-deadly breast cancers
    • Conquer the problems of overdiagnosis and overtreatment
    • Identify what drives breast cancer growth; determine how to stop it
    • Identify why some breast cancers become metastatic
    • Determine why/how breast cancer cells lay dormant for years and then re-emerge (recurrence); determine how to prevent recurrence
    • Revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival
    • Eliminate the mortality associated with metastatic breast cancer

    Breakthrough Award – Letter of Intent for levels 1 & 2, November 21

    • ·       Investigators at all academic levels (or equivalent)
    • Senior postdoctoral fellows who do not meet the eligibility requirements of the Breakthrough Fellowship Award are encouraged to apply under Funding Levels 1 and 2
    • Each investigator may submit only one Funding Level 1 application and one Funding Level 2 application as a PI or Initiating PI,
      Supports promising research that has the potential to lead to or make breakthroughs in breast cancer.
    • ·       Potential impact of the research may be near-term or long-term, but it must be significant and go beyond an incremental advancement.
    • ·       Partnering PI Option allows two Principal Investigators (PIs), termed Initiating and Partnering PIs, to collaborate on a single application.
    • ·        It is the responsibility of the PI to select the funding level that is most appropriate for the research proposed.  The funding level should be selected based on the scope of the research project, rather than the amount of the budget.
    • ·        There are no limitations on the number of applications for which an investigator may be named as a Partnering PI.  However, applicants are discouraged from submitting as a Partnering PI on multiple applications unless they are clearly unique, meaningful collaborations addressing distinct research questions.
    • ·        Additional funds are available for applications submitted under the Partnering PI Option.
    • ·        Clinical trials are not allowed.
    • ·        Submission of a Letter of Intent is required prior to full application submission.

    Funding Level 1:

    • ·       Maximum funding of $375,000 for direct costs (plus indirect costs)
    • ·       Maximum period of performance is 3 years

    Funding Level 1 – Partnering PI Option:

    • ·       Maximum funding of $600,000 for direct costs (plus indirect costs)
    • ·       Maximum period of performance is 3 years

    Funding Level 2:

    • ·       Maximum funding of $750,000 for direct costs (plus indirect costs)
    • ·       Maximum period of performance is 3 years

    Funding Level 2 – Partnering PI Option:

    • ·       Maximum funding of $1 million (M) for direct costs (plus indirect costs)
    • ·       Maximum period of performance is 3 years

    Breakthrough Award –Preproposal for levels 3 & 4 September 29

    • ·       Independent investigators at all academic levels (or equivalent) are eligible.
    • ·       Each investigator may submit only one Funding Level 3 pre-application and one Funding Level 4 pre-application as a PI or Initiating PI
    • ·       Supports promising research that has the potential to lead to or make breakthroughs in breast cancer.
    • ·       Potential impact of the research may be near-term or ling-term, but it must be significant and go beyond an incremental advancement.
    • ·       Partnering PI Option allows two PIs, termed Initiating and Partnering PIs, to collaborate on a single application.
    • ·       Is it the responsibility of the PI to select the funding level that is most appropriate for the research proposed.  The funding level should be selected based on the scope of the research project, rather than the amount of the budget.
    • ·       There are no limitations on the number of applications for which an investigator may be named as a Partnering PI.  However, applicants are discouraged from submitting as a Partnering PI on multiple applications unless they are clearly unique, meaningful collaborations addressing distinct research questions.
    • ·       PI’s must include two or more breast cancer advocates on their research team.
    • ·       Submission of a proposal is required: application submission is by invitation only.

    Funding Level 3:

    • ·       Maximum funding of $2.5M in direct costs (plus indirect costs)
    • ·       Maximum period of performance is 4 years

    Funding Level 3 – Partnering PI Option:

    • ·       Maximum funding of $4M for direct costs (plus indirect costs)
    • ·       Maximum period of performance is 4 years

    Funding Level 4 and Funding Level 4 – Partnering PI Option:

    • ·       Maximum funding of $10M for direct costs (plus indirect costs)

    Maximum period of performance is 4 years

    Breakthrough Fellowship Award – Letter of Intent due November 21

    As of the application submission deadline, all eligible PIs must have:

    • Successfully completed the requirements for a doctoral or medical degree, and
    • Been in the laboratory or clinical research setting in which the proposed research is to be performed for no more than 2 years, and

    ·       A total of less than 4 years experience in a postdoctoral fellowship or mentored clinical research training program (excludes any clinical residency or fellowship training)

    Mentor

    Must have breast cancer research experience, including current funding and recent publications

    • ·       Supports exceptionally talented, “best and brightest” recent doctoral or medical graduates in pursuit of promising research that has the potential to lead to or make breakthroughs in breast cancer.
    • ·       Potential impact of the research may be near-term or long-term, but it must be significant and go beyond an incremental advancement.
    • ·       Individualized researcher development plan and mentorship should prepare the PI for an independent career at the forefront of breast cancer research or patient care.
    • ·       The PI is not required to have previous experience in breast cancer research.
    • ·       Preliminary data are allowed, but not required.
    • ·       Maximum funding of $300,000 for direct costs (plus indirect costs)
    • Maximum period of performance is 3 years

    Era of Hope Scholar Award – Letter of Intent due November 21

    Must be an independent, non-mentored investigators within 6 years of their last training position (e.g., postdoctoral fellowship, medical residency, clinical fellowship) as of the application submission deadline

    • ·       Supports exceptionally talented, creative early-career scientists who have demonstrated that they are the “best and brightest” in their fields.
    • ·       PIs should articulate a vision that challenges current dogma and demonstrates an ability to look beyond tradition and convention.
    • ·       PIs must exhibit strong potential for leadership in breast cancer.
    • ·       Experience in breast cancer is not required: however, the application must focus on breast cancer, and the PI must maintain a 50% dedication of his/her full-time professional effort during the award period to breast cancer research.
    • PIs must include breast cancer advocates on their research team.
    • Submission of a Letter of Intent is required prior to full application submission.
    • ·        Maximum funding of $2.5M for direct costs (plus indirect costs)
    • Maximum period of performance is 4 years

    Innovator Award – Pre-application due September 29

    Must be an Associate Professor or above (or equivalent).

    • ·       Supports visionary individuals who have demonstrated creativity, innovative work, and leadership in any field.
    • ·       Provides opportunity to pursue novel, visionary, high-risk ideas that will accelerate progress toward ending breast cancer.
    • ·       Experience in breast cancer research is not required: however, the application must focus on breast cancer, and the PI must maintain a 50% dedication of his/her full-time professional effort during the award period to breast cancer.
    • ·       PIs must include breast cancer advocates on their research team.
    • Preproposal is required; application submission is by invitation only.
    • ·        Maximum funding of $5M for direct costs (plus indirect costs).
    • Maximum period of performance is 4 years.

    Distinguished Investigator Award – Pre-application due September 29

    PIs must be at or above the level of Assistant Professor (or equivalent) and more than 6 years beyond the PI’s last training position as of the application submission deadline

    • ·       Supports established visionary leaders from any filed to pursue innovative ideas that could accelerate progress toward ending breast cancer.
    • ·       The PI must propose research that is a fundamental shift from his/her track record of research.
    • ·       Does not support continuation of or incremental change from the PI’s published line of research.
    • ·       If the PI is an established breast cancer researcher, he/she must clearly articulate a motivation and commitment for proposing a fundamental shift in his/her research and must include at least one collaborator with breast cancer expertise.
    • ·       High-risk/high-reward projects pursuing innovative new paradigms are encouraged, but not required.
    • ·       PIs must include two or more breast cancer advocates on their research team.
    • Submission of a preproposal is required; application submission is by invitation only.
    • ·        Maximum funding of $3M for direct costs (plus indirect costs)
    • Maximum period of performance is 4 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the BCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk
    301-682-5507
    help@eBrap.org


<< First  < Prev   1   2   Next >  Last >> 

1717 K ST NW Suite 900

Washington, DC 20006

P: 301-656-5005  |  admin@navref.org

Powered by Wild Apricot Membership Software